[ad_1]
- A small examine discovered that the favored weight reduction drug semaglutide might assist decrease the danger of growing heart problems.
- After one yr, examine contributors confirmed enhancements in a number of cardiovascular danger elements, together with blood strain, whole ldl cholesterol, and triglycerides.
- Some specialists counsel that by treating weight problems, Ozempic seems to lower danger elements that may result in coronary heart illness.
New analysis has discovered that the favored weight reduction drug semaglutide, bought beneath the model names Wegovy and Ozempic, might assist decrease the danger of growing cardiovascular disease, too.
The findings, introduced at this yr’s European Congress on Obesity in Dublin, Ireland, discovered that a number of cardiovascular danger elements, together with blood strain, whole ldl cholesterol, and triglycerides, decreased after a yr of taking semaglutide.
Cardiologists imagine that the anti-obesity drug boosts coronary heart well being by bettering these danger elements, that are confirmed to contribute to coronary heart illness.
Though extra analysis is required to raised perceive the results of semaglutide, the findings counsel that individuals in danger for coronary heart illness might doubtlessly profit from taking semaglutide.
“In this small retrospective study amongst individuals who were overweight or obese, it appears that use of a specific agent targeting overall weight loss improved cardiovascular risk as measured by one well-utilized risk calculator,” Ajaykumar D. Rao, MD, MMSc, FACP, Chief of the Section of Endocrinology, Diabetes and Metabolism and Associate Professor of Medicine on the Lewis Katz School of Medicine at Temple University, who was not a part of the unique examine, informed Healthline.
To perceive the impact semaglutide has on heart problems in people who find themselves obese or have obesity, the researchers evaluated the well being information of 93 sufferers with a physique mass index (BMI) of 27 kg/m2 or greater who had no historical past of heart problems.
Using their demographic, medical, and lipid panel information, they calculated every affected person’s 10-year atherosclerotic heart problems (10-year ASCVD) danger earlier than beginning semaglutide after which after one yr of taking semaglutide.
The 10-year ASCVD danger estimator is a software created by the American College of Cardiology that predicts an individual’s 10-year danger of growing atherosclerotic heart problems.
It’s used to information potential therapy plans in individuals in danger for coronary heart illness.
The workforce discovered that the 10-year ASCVD dropped by 1.38 p.c, from 7.64 p.c earlier than taking semaglutide to six.26 p.c after 12 months of taking the anti-obesity drug.
The researchers additionally measured a number of cardiovascular danger elements, together with whole physique weight reduction share, change in blood pressure, HbA1c (a measure of blood sugar management), fasting glucose, lipid panel, blood pressure medications, and use of aspirin and statin earlier than the sufferers started taking semaglutide and at and their final follow-up go to.
After a yr of taking semaglutide, the contributors’ blood strain dropped considerably — on common, by 9.3/4.9 mmHg — as did their whole ldl cholesterol, LDL ldl cholesterol, triglycerides, fasting glucose, and HbA1c.
Patients additionally misplaced a mean of 10.9 p.c of their physique weight.
There had been some limitations of the report.
Supreeti Behuria, MD, a heart specialist at Staten Island University Hospital, says the examine included a small pattern dimension of fewer than 100 individuals and it had a brief follow-up time of lower than one yr. Behuria was not concerned within the analysis.
“Almost 91 percent of patients were white, so this study did not represent our diverse patient population and I wonder at its applicability in the broader context,” Behuria mentioned.
While the report suggests Ozempic might have optimistic results on cardiovascular well being, extra analysis with bigger pattern sizes and longer follow-up intervals is required to raised perceive the brief and long-term impacts.
Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, says there are a number of mechanisms by which weight problems will increase the danger of heart problems — primarily, that weight problems will increase atherosclerotic plaque buildup in arteries, placing individuals in danger for myocardial infarction. Ali was additionally not a part of the unique analysis.
The improve in physique fats in weight problems contributes to different danger elements for coronary heart illness like hypertension, diabetes, and obstructive sleep apnea, says Behuria.
“In my opinion, it is not the medication itself that is lowering heart disease risk, but the weight loss as a result of taking it,” Ali mentioned.
Obesity is without doubt one of the most targetable and modifiable danger elements for weight problems, in line with Rao.
“Semaglutide is [a] medication that helps reduce body weight and thus treats obesity. By treating obesity, helps decrease cardiovascular risk factors which further lower the risk of cardiovascular disease,” Behuria mentioned.
New analysis has discovered that the favored weight reduction drug semaglutide might assist decrease the danger of growing heart problems, too.
Multiple cardiovascular danger elements, together with blood strain, whole ldl cholesterol, and triglycerides, improved after a yr of taking semaglutide.
By treating weight problems, semaglutide seems to lower danger elements that may result in coronary heart illness.
[adinserter block=”4″]
[ad_2]
Source link